Botulinum Toxin Type A for the Treatment of Glabellar Lines in Chinese: A Double-Blind, Randomized, Placebo-Controlled Study
Article first published online: 7 DEC 2009
© 2009 by the American Society for Dermatologic Surgery, Inc.
Volume 36, Issue 1, pages 102–108, January 2010
How to Cite
WU, Y., ZHAO, G., LI, H., ZHENG, Z., ZHONG, S., YANG, Z., FENG, Z., YANG, Q. and ZHU, X. (2010), Botulinum Toxin Type A for the Treatment of Glabellar Lines in Chinese: A Double-Blind, Randomized, Placebo-Controlled Study. Dermatologic Surgery, 36: 102–108. doi: 10.1111/j.1524-4725.2009.01390.x
- Issue published online: 18 DEC 2009
- Article first published online: 7 DEC 2009
BACKGROUND This is the first well-controlled study of the use of botulinum toxin type A (BoNTA) for glabellar lines in China.
OBJECTIVES To evaluate the safety and efficacy of BoNTA in the treatment of glabellar lines in Chinese subjects.
MATERIALS AND METHODS A total of 227 subjects received a single treatment in a 3:1 randomization ratio of BoNTA (20 U):placebo and were observed for 120 days after injection. Effective outcome measures included investigator's rating of wrinkle severity at maximum frown and rest and subjects' global assessment and self-perception of age.
RESULTS A significantly higher responder rate at maximum frown, ranging from 94.1% at day 30 to 52.9% at day 120, was noted in the BoNTA group. The proportion of subjects with none or mild glabellar lines at rest was 66.7% in the BoNTA group at day 30. Most (95.3%) of the subjects treated with BoNTA reported better than 50% improvement at day 30, and self-perception of age was less than chronological age. There were no statistically significant differences in adverse events reported between the two groups (p=.06).
CONCLUSION A single treatment of 20 U of BoNTA was effective and safe in reducing glabellar lines in Chinese subjects.
GlaxoSmithKline provided funding and study material.